The poster “Real-world treatment persistence and associated costs with biologic therapy in patients with Inflammatory Bowel Disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in Germany” will be presented at the 13th Congress of ECCO – Inflammatory Bowel Diseases 2018 (February 14-17, 2018 in Vienna, Austria). It summarizes the first results of an ongoing claims data study to describe the epidemiology and prevalence of IBD patients treated with biologic agents in Germany. Treatment patterns and IBD-related costs were compared between anti-TNF and Vedolizumab treated individuals. The analysis is based on claims data of several German statutory health insurance funds representing approximately 8 million insured persons.

The poster can be downloaded from here.